Longboard Pharmaceuticals Inc LBPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LBPH is a good fit for your portfolio.
News
-
Longboard Pharmaceuticals' Potential Seizure Treatment Gets FDA's Breakthrough Therapy Designation
-
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
-
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
-
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Trading Information
- Previous Close Price
- $30.65
- Day Range
- $31.00–31.24
- 52-Week Range
- $3.60–33.56
- Bid/Ask
- $30.59 / $31.19
- Market Cap
- $1.21 Bil
- Volume/Avg
- 133 / 426,368
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 33
- Website
- https://www.longboardpharma.com
Comparables
Valuation
|
Metric
|
LBPH
|
GBIO
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.81 | 1.18 | 12.65 |
Price/Sales | — | 15.51 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
LBPH
GBIO
CBAY
Financial Strength
|
Metric
|
LBPH
|
GBIO
|
CBAY
|
|---|---|---|---|
Quick Ratio | 31.20 | 7.75 | 10.70 |
Current Ratio | 31.43 | 8.01 | 10.96 |
Interest Coverage | — | — | −5.27 |
Quick Ratio
LBPH
GBIO
CBAY
Profitability
|
Metric
|
LBPH
|
GBIO
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −46.00% | −23.97% | −30.06% |
Return on Equity (Normalized) | −49.96% | −40.92% | −51.97% |
Return on Invested Capital (Normalized) | −54.01% | −33.29% | −30.87% |
Return on Assets
LBPH
GBIO
CBAY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rfnggbbkn | Sgcn | $636.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gcqlcgj | Gffvfps | $122.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jtcggddy | Vxmpvv | $115.1 Bil | |||
| Moderna Inc
MRNA
| Zmclqkhj | Pkpt | $44.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dhbhrhzf | Nmhykm | $31.3 Bil | |||
| argenx SE ADR
ARGX
| Hcnnlnftb | Ljn | $26.2 Bil | |||
| BioNTech SE ADR
BNTX
| Fskgxyst | Xvsc | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hcflgkcb | Blcbkxh | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Sdhdypyc | Pscf | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Pjbssldqp | Qjbrxd | $11.7 Bil |